Delpharm
Delpharm, a leading contract development and manufacturing organisation (CDMO), is headquartered in France and operates extensively across Europe and beyond. Founded in 1998, Delpharm has established itself as a key player in the pharmaceutical industry, specialising in the production of solid forms, liquids, and semi-solids. The company is renowned for its commitment to quality and innovation, offering tailored solutions that meet the diverse needs of its clients. Delpharm's state-of-the-art facilities and adherence to stringent regulatory standards have positioned it as a trusted partner for pharmaceutical companies worldwide. With a focus on sustainability and efficiency, Delpharm continues to achieve significant milestones, reinforcing its reputation as a reliable provider in the competitive landscape of pharmaceutical manufacturing.
DitchCarbon Score
How does Delpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Delpharm's score of 9 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Delpharm's reported carbon emissions
In 2023, Delpharm reported total carbon emissions of approximately 695,610,000 kg CO2e across all scopes. This includes about 35,365,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and approximately 20,362,000 kg CO2e from Scope 2 emissions, related to purchased electricity. The majority of their emissions, around 695,610,000 kg CO2e, fall under Scope 3, which includes indirect emissions from the value chain, such as purchased goods and services, employee commuting, and downstream transportation. Delpharm has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, the company is actively engaged in monitoring and reporting its emissions, which is a crucial step towards understanding and managing its carbon footprint. As the pharmaceutical industry increasingly focuses on sustainability, Delpharm's commitment to transparency in emissions reporting aligns with broader industry trends aimed at reducing environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 35,365,000 |
| Scope 2 | 20,362,000 |
| Scope 3 | 695,610,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Delpharm is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
